title: Fixation control before and after treatment for neovascular age-related macular degeneration.
abstract: OBJECTIVE
  We studied changes in visual acuity (VA), fixation stability, and location of the preferred retinal locus (PRL) after treatment for unilateral neovascular age-related macular degeneration (AMD) for previously untreated eyes. Concomitant changes in fixation stability, PRL, and VA in the untreated fellow eye were also analyzed.
  
  
  METHODS
  Pre- and posttreatment tests of visual acuity, fixation stability, and PRL location in both the treated and the untreated eyes were performed on 13 patients undergoing three monthly intravitreal injections of ranibizumab in one eye.
  
  
  RESULTS
  For the treated eyes there were improvements in VA and fixation stability but no changes in the location of the PRL. No significant changes in any of the three variables were found in the untreated eye.
  
  
  CONCLUSIONS
  For previously untreated eyes, the improvement in visual acuity after intravitreal ranibizumab injections was accompanied by improvement in fixation stability.
authors.affiliation: Vision Science Research Program, Toronto Western Hospital, Toronto, Canada. gonzalez@yorku.ca
authors.forename: Esther G
authors.initials: EG
authors.lastname: González
authors.forename: Luminita
authors.initials: L
authors.lastname: Tarita-Nistor
authors.forename: Efrem D
authors.initials: ED
authors.lastname: Mandelcorn
authors.forename: Mark
authors.initials: M
authors.lastname: Mandelcorn
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Steinbach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005403:Fixation, Ocular / Q000187:drug effects*; D006801:Humans; D008268:Macular Degeneration / Q000150:complications* / Q000503:physiopathology*; D008297:Male; D000069579:Ranibizumab; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab